Gregory S. Calip
Affiliate, Center for Pharmacoepidemiology and Pharmacoeconomic Research
Director, UIC-AbbVie Fellowship in Pharmacovigilance and Patient Safety
Member, Cancer Prevention and Control Research Program
Associate Professor, Pharmacy Systems, Outcomes and Policy
Teaching and Supervision
Independent Study (PSOP 596), 6/14/2021 – 8/6/2021
Ph.D. Thesis Research (PSOP 599), 1/11/2021 – 4/30/2021
PSOP Project (PSOP 597), 1/11/2021 – 4/30/2021
Projects Pharm Syst Outcomes (PSOP 390), 1/11/2021 – 4/30/2021
Independent Study (PSOP 596), 1/11/2021 – 4/30/2021
Epidemiology/Biostatistics (PHAR 439), 1/11/2021 – 2/12/2021
Epidemiology/Biostatistics (PHAR 439), 1/11/2021 – 2/12/2021
Spec Topic Pharm Syst Outcomes (PSOP 594), 8/24/2020 – 12/4/2020
Ph.D. Thesis Research (PSOP 599), 8/24/2020 – 12/4/2020
3/3: The Chicago Cancer Health Equity Collaborative (ChicagoCHEC), National Institutes of Health (National Cancer Institute)., 9/22/2020 - 8/31/2025, Obligated Amount: $1366169; Anticipated Amount: $6834852
Increasing the cure fraction in myeloma- a novel strategy to personalize melphalan dosing and overcome DNA repair-mediated resistance, UIC College of Pharmacy., 8/1/2020 - 7/31/2021, Obligated Amount: $25000; No Anticipated Amount Set
Incoming MTA - Trends of opioid prescribing by dentits, National Institutes of Health (National Cancer Institute)., 7/29/2020 - 7/28/2023, No Obligated Amount Set; No Anticipated Amount Set
Novel gut microbial biomarkers and the adverse metabolic effects of atypical antipsychotics, National Institutes of Health., 4/2020 - 3/2022, No Obligated Amount Set; No Anticipated Amount Set
Pilot Study to Develop and Test a Multiplex Assay for CYP450 Phenotyping in Multiple Myeloma Patients Receiving Bortezomib, Hematology Oncology Pharmacy Association (HOPA)., 3/1/2020 - 2/28/2022, Obligated Amount: $85283; Anticipated Amount: $85283
Prevention of Venous Thromboembolism in Multiple Myeloma: The Thromboprophylaxis Multi-Cohort Study, National Institutes of Health., 12/2019 - 11/2023, No Obligated Amount Set; No Anticipated Amount Set
UIC Subaward for Dental prescribing of antibiotics and opioids: high use in the absence of evidence, University of Pittsburgh., 11/1/2019 - 7/31/2021, Obligated Amount: $360368; Anticipated Amount: $360368
Surveillance, Epidemiology, and End Results based Real-World Evidence in EArLy Breast Cancer (SEER-REAL-BC) Studies: Patient Characteristics, Treatment Patterns, and Outcomes in Patients with HR+/HER2- early-stage breast cancer, Pfizer., 8/19/2019 - 8/19/2021, No Obligated Amount Set; No Anticipated Amount Set
Pfizer outcomes research agreement, Pfizer Inc., 8/19/2019 - 8/19/2021, Obligated Amount: $396464; Anticipated Amount: $396464
Zhou, J, Cueto, J, Ko, NY, Hoskins, KF, Nabulsi, NA, Asfaw, AA, Hubbard, CC, Mitra, D, Calip, GS, Law, EH. (2021). Population-based recurrence rates among older women with HR-positive, HER2-negative early breast cancer: Clinical risk factors, frailty status, and differences by race. Breast, 59, 367-375. doi:10.1016/j.breast.2021.08.005.
Hoskins, KF, Calip, GS. (2021). Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay among Women with Breast Cancer – Reply. JAMA Oncology, 7, (8), 1248-1249. doi:10.1001/jamaoncol.2021.1959.
Calip, GS, Miksad, RA, Sarkar, S. (2021). Time-Related Biases in Nonrandomized COVID-19-Era Studies Using Real-world Data. JAMA Oncology, 7, (8), 1175-1177. doi:10.1001/jamaoncol.2021.1715.
Guadamuz, JS, Durazo-Arvizu, RA, Daviglus, ML, Calip, GS, Nutescu, EA, Qato, DM. (2021). Statin nonadherence in Latino and noncitizen neighborhoods in New York City, Los Angeles, and Chicago, 2012-2016. Journal of the American Pharmacists Association, 61, (4), e263-e278. doi:10.1016/j.japh.2021.01.032.
Calip, GS, Yerram, P, Ascha, MS. (2021). Nonrandomized Comparison of Adverse Events following Facility- And Home-Infused Biologics Using Real-World Data. JAMA Network Open, 4, (6). doi:10.1001/jamanetworkopen.2021.11156.
Takvorian, Samuel U, Parikh, Ravi Bharat, Vader, Daniel, Wileyto, E Paul, Clark, Amy Sanders, Lee, Daniel J, Goyal, Gaurav, Rocque, Gabrielle Betty, Dotan, Efrat, Geynisman, Daniel M, Phull, Pooja, Spiess, Philippe E, Kim, Roger, Davidoff, Amy J, Gross, Cary Philip, Miksad, Rebecca A, Calip, Gregory Sampang, Shulman, Lawrence N, Mamtani, Ronac, Hubbard, Rebecca A. (2021). Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer.. Journal of Clinical Oncology, 39, (15_suppl), 1528-1528. doi:10.1200/jco.2021.39.15_suppl.1528.
Wang, Xiaoliang, Ascha, Mustafa, Green, Tammy, Lewin, Heather G, Showalter, Timothy N, Goldstein, Lori J, Calip, Gregory Sampang, Whitaker, Kristen Danielle. (2021). Racial disparities in second-line (2L) treatment and overall survival among patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC) treated in routine practice.. Journal of Clinical Oncology, 39, (15_suppl), 6541-6541. doi:10.1200/jco.2021.39.15_suppl.6541.
Hoskins, Kent, Calip, Gregory Sampang, Danciu, Oana Cristina, Rauscher, Garth H. (2021). What accounts for the racial disparity in survival from estrogen receptor-positive, axillary node-negative breast cancer in the United States? An analysis of the SEER-Oncotype database.. Journal of Clinical Oncology, 39, (15_suppl), 6534-6534. doi:10.1200/jco.2021.39.15_suppl.6534.
Hanson, Kent, Hoskins, Kent, Ko, Naomi Yu, Calip, Gregory Sampang. (2021). Multi-gene prognostic assays and age-related differences in prediction of pathologic complete response to neoadjuvant chemotherapy and survival in breast cancer.. Journal of Clinical Oncology, 39, (15_suppl), 591-591. doi:10.1200/jco.2021.39.15_suppl.591.
NIH Center for Scientific Review, 9/7/2020 - 9/9/2020
PharmD, University of Illinois at Chicago, United States, 2008
MPH, New York University, United States, 2010
PhD, University of Washington, United States, 2014
NCI Cancer Prevention Training Grant in Nutrition, Exercise and Genetics, Fred Hutchinson Cancer Research Center, United States, 2014
Licensures and Certifications
Registered Pharmacist, Washington State, Date Not Set - Present
Registered Pharmacist, New York State, Date Not Set - Present
Registered Pharmacist, Illinois State, Date Not Set - Present
Immunization Provider, APhA, Date Not Set - Present
CPR-AED Training, American Red Cross, Date Not Set - Present
Pharmacy Provider, NPI, Date Not Set - Present